150
Participants
Start Date
April 30, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
Iron (III) Hydroxide Polymaltose (50 mg/5 mL)
"Participants randomized to the intervention group will receive oral iron supplementation in addition to a gluten-free diet. The specific iron formulation used in this study is Iron (III) Hydroxide Polymaltose (50 mg/5 mL) at a dosage of 6 mg/kg/day, up to a maximum of 100 mg/day, for 3 months.~The iron supplement will be given once daily, preferably on an empty stomach or with vitamin C-containing foods to enhance absorption. Parents/caregivers will be instructed on proper administration, and adherence will be monitored through weekly self-reported intake logs and pharmacy dispensing records.~This intervention is specifically targeted at children with newly diagnosed celiac disease and iron deficiency without anemia.~The study follows a non-inferiority design, comparing the effect of iron supplementation versus a gluten-free diet alone on ferritin levels."
Gluten-free diet
Participants in the control group will follow a strict gluten-free diet, the standard-of-care treatment for celiac disease. No iron supplementation will be given. Compliance will be monitored through self-reported adherence and TTG antibody levels at follow-up.
Rambam Medical Center, Haifa
Meir Medical Center, Kfar Saba
Schneider Children's Medical Center, Petah Tikva
Kaplan Medical Center, Rehovot
Assuta Ashdod Medical Center, Ashdod
Lead Sponsor
Collaborators (1)
Schneider Children's Hospital
OTHER
Rambam Hospital, Haifa, Israel
UNKNOWN
Meir Medical Center
OTHER
Assuta Ashdod Hospital
OTHER
Kaplan Medical Center
OTHER